Global Patent Index - EP 1337248 A1

EP 1337248 A1 20030827 - METHODS FOR TREATMENT OF INFLAMMATORY DISEASES

Title (en)

METHODS FOR TREATMENT OF INFLAMMATORY DISEASES

Title (de)

VERFAHREN ZUR BEHANDLUNG VON ENTZÜNDUNGSERKRANKUNGEN

Title (fr)

METHODE DE TRAITEMENT DE MALADIES INFLAMMATOIRES

Publication

EP 1337248 A1 20030827 (EN)

Application

EP 01937283 A 20010509

Priority

  • US 0115102 W 20010509
  • US 57026600 A 20000512
  • US 75869601 A 20010111

Abstract (en)

[origin: WO0187301A1] An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone. In still another alternative, the emulsifier system can include cetyl alcohol and stearic acid. In yet another alternative, the emulsifier system can include sodium stearoyl lactylate and sodium isostearoyl lactylate. In another alternative, the emulsifier system can include at least one polyethyleneglycol ether of cetearyl alcohol. In still another alternative, the emulsifier system can include a polyethylene glycol ester of stearic acid and glyceryl stearate. The composition can include other ingredients. The pH of the composition used in a method according to the present invention is from about 3.0 to about 6.0; preferably, a narrower pH range is used, varying with each embodiment of the composition. Among the diseases that can be treated is epidermolysis bullosa.

IPC 1-7

A61K 31/415; A61K 7/00; A01N 43/50

IPC 8 full level

A61K 9/107 (2006.01); A61K 8/06 (2006.01); A61K 8/37 (2006.01); A61K 8/46 (2006.01); A61K 8/49 (2006.01); A61K 8/73 (2006.01); A61K 8/81 (2006.01); A61K 8/86 (2006.01); A61K 8/92 (2006.01); A61K 31/4166 (2006.01); A61K 45/00 (2006.01); A61K 47/14 (2006.01); A61K 47/16 (2006.01); A61K 47/20 (2006.01); A61K 47/36 (2006.01); A61K 47/44 (2006.01); A61P 17/02 (2006.01); A61Q 19/00 (2006.01)

CPC (source: EP)

A61K 8/06 (2013.01); A61K 8/062 (2013.01); A61K 8/37 (2013.01); A61K 8/463 (2013.01); A61K 8/4946 (2013.01); A61K 8/73 (2013.01); A61K 8/8147 (2013.01); A61K 8/86 (2013.01); A61K 8/927 (2013.01); A61K 9/0014 (2013.01); A61K 47/20 (2013.01); A61K 47/44 (2013.01); A61P 17/02 (2017.12); A61Q 19/00 (2013.01)

Citation (search report)

See references of WO 0187301A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0187301 A1 20011122; WO 0187301 A9 20021219; AU 6303501 A 20011126; BR 0110775 A 20040720; CA 2408163 A1 20011122; CN 1441672 A 20030910; EP 1337248 A1 20030827; JP 2003533481 A 20031111; MX PA02011159 A 20040819

DOCDB simple family (application)

US 0115102 W 20010509; AU 6303501 A 20010509; BR 0110775 A 20010509; CA 2408163 A 20010509; CN 01812651 A 20010509; EP 01937283 A 20010509; JP 2001583769 A 20010509; MX PA02011159 A 20010509